Soolantra is an anti-rosacea drug owned by Galderma Labs Lp and was authorized for market use on December 19, 2014. It contains active ingredient ivermectin and is available in cream; topical dosage forms.
The generic version of Soolantra may be available after March 13, 2034. The last patent protecting it is set to expire on that date, which could open the way for the production of generics.
Soolantra is used for the treatment of inflammatory lesions of rosacea. Its active ingredient, ivermectin, has proven potential in dealing with this skin condition.
Soolantra is protected by 12 patents, none of which have expired. The last patent protecting Soolantra generic is due to expire on March 13, 2034. Below are the details of the patent: